Valérie VILGRAIN GROUP

Valérie Vilgrain is Director of the Radiology Department at the University Hospital Beaujon in Clichy (France) and full professor at the University Paris Diderot (France). Her research topics are diagnostic and interventional imaging of the liver and bile ducts with CT and MRI. She received her MD from the René Descartes Medical University of Paris in 1985. She completed a residency in Radiology and was assistant Professor in Radiology at the University Hospital Beaujon. She is member of several international societies (Radiological Society of North America, European Society of Radiology, European Society of Gastroenterology and Abdominal Radiology), and the French Radiology Society. She was responsible for the Education Program Committee of the French annual meeting from 2000 to 2008 and she is currently Vice-Director of the French Radiology Society. She published numerous peer-reviewed articles (h-index: 57) and is reviewer for many renowned journals including European Radiology, Liver Transplantation, Hepatology, Journal of Hepatology, Radiology, and European Journal of Radiology. She is associate editor of Radiology.

  • J Hepatol. 2020;72:937-945. Comparison of extracellular and hepatobiliary MR Contrast agents for the diagnosis of small HCCs. APaisant, V Vilgrain, J Riou, F Oberti, O Sutter, V Laurent, A Rodes, B Guiu, C Cassinotto, H Trillaud, I Bricault, S Michalak, O Bruno, M Ronot, C Aubé. PubMed
  • Dig Dis Sci. 2019;64:934-950. Hepatocellular carcinoma: current imaging modalities for diagnosis and prognosis. Ronot M, Purcell Y, Vilgrain V. PubMed
  • Eur Radiol. 2019;In press. Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping. Reizine E, Ronot M, Pigneur F, Purcell Y, Mulé S, Dioguardi Burgio M, Calderaro J, Amaddeo G, Laurent A, Vilgrain V, Luciani A. PubMed
  • J Hepatol. 2018;69:182-236. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, Schirmacher P, Vilgrain V. PubMed
  • AJR Am J Roentgenol. 2018;210:775-779. Focal nodular hyperplasia after treatment with Oxaliplatin: A multiinstitutional series of cases diagnosed at MRI. Furlan A, Brancatelli G, Dioguardi Burgio M, Grazioli L, Lee JM, Murmura E, Lucidarme O, Strauss C, Rode A, Ronot M, Vilgrain V. PubMed
  • Lancet Oncol. 2017;18:1624-1636. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group. PubMed
  • JMIR Res Protoc. 2017;6:e17. VESPRO: An individual patient data prospective meta-analysis of selective internal radiation therapy versus Sorafenib for advanced, locally advanced, or recurrent hepatocellular carcinoma of the SARAH and SIRveNIB trials. Gebski V, Gibbs E, Gandhi M, Chatellier G, Dinut A, Pereira H, Chow PK, Vilgrain V. PubMed
  • Eur J Drug Metab Pharmacokinet. 2017;42:657-667. Liver perfusion modifies Gd-DTPA and Gd-BOPTA hepatocyte concentrations through transfer clearances across sinusoidal membranes. Daire JL, Leporq B, Vilgrain V, Van Beers BE, Schmidt S, Pastor CM5. PubMed
  • Semin Ultrasound CT MR. 2016;37:561-572. Avoiding pitfalls in the interpretation of Gadoxetic Acid-enhanced Magnetic Resonance Imaging. Dioguardi Burgio M, Ronot M, Paulatto L, Terraz S, Vilgrain V, Brancatelli G. PubMed
  • Liver Int. 2016;36:631-3. Multiparametric magnetic resonance imaging in patients with chronic liver disease: are we there yet? Ronot M, Vilgrain V. PubMed
  • J Hepatol. 2016;64:708-16. Insights into the diagnosis of hepatocellular carcinomas with hepatobiliary MRI.Vilgrain V, Van Beers BE, Pastor CM. PubMed
  • Eur Radiol. 2016;26:921-31. ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Neri E, Bali MA, Ba-Ssalamah A, Boraschi P, Brancatelli G, Alves FC, Grazioli L, Helmberger T, Lee JM, Manfredi R, Martì-Bonmatì L, Matos C, Merkle EM, Op De Beeck B, Schima W, Skehan S, Vilgrain V, Zech C, Bartolozzi C. PubMed
  • Radiology. 2015;274:379-86. Advanced fibrosis: Correlation between pharmacokinetic parameters at dynamic gadoxetate-enhanced MR imaging and hepatocyte organic anion transporter expression in rat liver. Lagadec M, Doblas S, Giraudeau C, Ronot M, Lambert SA, Fasseu M, Paradis V, Moreau R, Pastor CM, Vilgrain V, Daire JL, Van Beers BE. PubMed
  • Best Pract Res Clin Gastroenterol. 2014;28:795-812. Hepatocellular carcinoma: diagnostic criteria by imaging techniques. Ronot M, Vilgrain V. PubMed
  • Clin Res Hepatol Gastroenterol. 2014;38:681-8. Imaging of benign hepatocellular lesions: current concepts and recent updates. Ronot M, Vilgrain V. PubMed
  • Trials. 2014;15:474.  Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M, Lebtahi R, Castéra L, Chatellier G; SARAH Trial Group. PubMed

PubMed

Clichy, France

Last update: August 2021